Purpose of review Seasonal and pandemic influenza are major causes of morbidity and mortality globally. Neuraminidase inhibitors (NAIs) are the only class of antiviral agent recommended for the treatment of currently circulating strains of influenza. There has previously been controversy over the level of evidence for patient benefit with NAIs. We review here the current evidence base for the clinical impact of treatment of influenza with NAIs.
INTRODUCTION
Neuraminidase inhibitors (NAIs) represent the only drug class currently recommended for the treatment of influenza [1] [2] [3] . During the 2009 influenza pandemic, NAIs were implemented as the key pharmacological intervention in addition to vaccination, and had been stockpiled by many public health agencies in preparation for such an event [4, 5, 6 && ]. Despite the global experience of using NAIs during the pandemic, some evidence gaps remain to be addressed to inform planning for future pandemic events and appropriate deployment in seasonal influenza infection.
NAIs are highly selective competitive inhibitors of neuraminidase, a glycoprotein located on the influenza virus membrane. Neuraminidase promotes the liberation of progeny virions from the infected host cells, by cleaving sialic residues on cellsurface receptors which are key attachment sites for influenza A and B viruses, therefore making it a key drug target within the viral replication cycle. Inhibition of this process is the accepted mechanism by which NAIs exert their influenza-specific antiviral effect [7] [8] [9] .
Establishing the crystal structure of the highly conserved antigen neuraminidase in 1983 [10] , allowed rational computer-assisted drug design, and the development of the highly selective reversible NAI, zanamivir (GSK, London, UK), first approved for use in 1999. An inhibitor of influenza A and B neuraminidases and delivered by the inhalation route, zanamivir had clear advantages over the M2 inhibitors amantadine and rimantadine, whose antiviral spectrum is restricted to influenza A and has been subsequently complicated by widespread resistance in currently circulating strains. The oral NAI oseltamivir (F. Hoffman-La Roche, Basel, Switzerland) was subsequently developed following modifications including the use of a cyclohexene ring and lipophilic side chain [7] [8] [9] 11] , and is globally now the most commonly used NAI. During the first 8 months alone of the H1N1 2009 influenza pandemic, it is estimated that more than 18 million people worldwide received oseltamivir [12] .
The most recent additions to the NAI class are peramivir, delivered as a single intravenous dose and laninamivir delivered as a single inhalational dose, both active against influenza A and B. Their use to date has been limited, however, with laninamivir currently only approved for use in Japan and peramivir approved for use in United States, Japan, South Korea and China [8] . Intravenous zanamivir has since been used on a compassionate basis for severely ill patients with a poor clinically response to oseltamivir and suspected or proven resistance [1] . It has been evaluated in a phase 2 randomized controlled trial and was shown not to be superior to standard doses of oral oseltamivir in adults with oseltamivir-sensitive influenza [13] . Table 1 shows the different NAIs and their properties.
Approaches to NAI treatment strategies within the 2009 pandemic worldwide ranged from no use, the targeted use for high risk individuals (most common) and a 'treat all' strategy for patients presenting with clinical illness, which was consistently applied within Japan [6 && ]. These strategies employed NAIs (most commonly oseltamivir) as monotherapy. Trials evaluating the impact of combinations of antivirals (including adamantanes and ribavirin) have had conflicting results. A recent phase 2 double-blinded randomised controlled trial did not find a combination of oseltamivir, amantadine and ribavirin to be associated with improved clinical outcomes compared with oseltamivir monotherapy [14] . Treatment is recommended to start as early as possible and without waiting for laboratory confirmation due the delays in obtaining results from centralized laboratory testing. Definitions of uncomplicated and complicated influenza are given in Table 2 . Risk factors for development of
NATIONAL AND INTERNATIONAL GUIDELINES

KEY POINTS
Randomized placebo-controlled trials demonstrate that NAIs reduce the duration of influenza symptoms in community-dwelling patients but increase the risk of nausea and vomiting.
Observational data suggest a reduction in hospitalization with outpatient NAI treatment in community-dwelling patients.
Well-controlled observational data suggest that NAI use reduces mortality in hospitalized adults with influenza especially when given early in the course of illness. This is aligned with national and international guidelines in recommending the liberal early use of NAIs in hospitalized patients. complications are shown in Table 3 . PHE guidelines are strongly aligned with US CDC [3] and WHO guidelines [2] .
EVIDENCE IN PATIENTS WITH UNCOMPLICATED INFLUENZA IN THE COMMUNITY
In 2014, a Cochrane review evaluated randomized controlled trial data on NAI use including previously unavailable pharmaceutical company study reports and regulators' comments. The Cochrane group examined data from 46 trials (20 oseltamivir and 26 zanamivir studies) for both treatment and prophylaxis in adults and children. The conclusions of the Cochrane review were that both drugs decreased the duration of influenza-like illness symptoms by around 0.5-1 day in adults. Considerable heterogeneity complicated the results for children. They reported that the effect of NAI treatment on the development of pneumonia and other complications was unreliably recorded in the trials for oseltamivir, preventing any firm conclusions. Oseltamivir use was associated with an increased risk of nausea, vomiting, renal and neuropsychiatric disorders [15 && ,16]. The major weakness of the Cochrane review is that the studies analyzed in it mainly involved community-dwelling healthy participants and excluded patients with significant comorbidities. Mortality was therefore a rare event, and the trials were not methodologically designed or powered to reliably detect differences in complications including hospitalization [15 && ,17] . The Cochrane review analyses therefore does not evaluate the patient groups who are most likely to benefit from influenza treatment, that is, those with comorbidities that put them at high risk of complications and those hospitalized with already severe influenza-related illness.
A subsequent meta-analysis (funded by an unrestricted grant from Roche) used individual patient data from nine randomized placebo-controlled trials of oseltamivir involving 4328 adult patients with influenza infection and demonstrated a similar reduction in the duration of symptoms to that seen in the Cochrane review. In addition, they concluded that oseltamivir treatment of influenza reduced the risk of lower respiratory tract complications and hospitalization. Although this analysis was based on the same trials included in the Cochrane review, the authors argue that using individual patient data rather than summative study reports allows a more thorough analysis of outcomes. This study also demonstrated an increased risk of nausea and vomiting with oseltamivir but did not find an association with neuropsychiatric disorders [18 && ]. A large randomized placebo-controlled trial of NAI treatment in uncomplicated influenza in Bangladeshi children showed a reduction in symptom duration of around 1 day and reduced viral shedding even when treatment was commenced 48 h or longer after symptom onset, although the benefit was greatest in those treated within 48 h. This study did not evaluate the effect of NAIs on complications or hospitalization [19] .
A meta-analysis of observational studies from the H1N1 2009 pandemic using individual participant data from 3376 patients, evaluated the effect of NAI treatment on hospital admission in patients with influenza (91% of which was laboratory confirmed) in the community and outpatient settings. It suggested that treatment with NAIs was associated with a reduced likelihood of hospital admission and that earlier treatment (<48 h of symptoms duration) was more beneficial than later treatment [20 & ]. Another meta-analysis of four observational studies including pre and postpandemic studies also suggested a reduction in hospitalization rate with oseltamivir treatment of outpatients but these studies did not adjust for important patient factors and were therefore deemed to be at high risk of bias [21] .
EVIDENCE IN HOSPITALIZED PATIENTS WITH COMPLICATED INFLUENZA
In contrast to the evidence base for NAI efficacy in the community setting, data in hospitalized patients are limited to observational studies, the interpretation of which is complicated by the inherently higher risk of bias in this type of study. Prior to the H1N1 2009 pandemic, several small observational studies evaluated the impact of NAI treatment in seasonal influenza, often in specific patient groups [22] [23] [24] [25] [26] .
Pre pandemic
Most prepandemic studies suggested that NAI treatment was associated with a reduction in mortality. A systematic review and meta-analysis of data including studies of hospitalized patients with seasonal influenza concluded that oseltamivir may be associated with reduced mortality compared with no antiviral treatment in high-risk populations. The overall quality of the evidence, however, was low because of the risk of confounding, selection and publication bias [21] .
Post pandemic
A systematic review and meta-analysis of patients of any age hospitalized in the H1N1 2009 H1N1 pandemic did not find a significant reduction in mortality with NAIs given at any time vs. no treatment. However, a reduction in mortality was found with early (<48 h after symptom onset) vs. late treatment (>48 h after symptom onset), and with early treatment vs. no treatment [27] . This was similar to the time-specific benefits seen in earlier observational studies [21] . Limitations of this analysis included heterogeneity of included studies and potential incomplete adjustment for confounding variables [27] . The authors postulate that the reason for the lack of an observed mortality benefit with NAI treatment vs. none was because of confounding by indication, so that more severely unwell patients were more likely to receive NAI treatment. They also noted a high degree of heterogeneity among included studies and a likely publication bias.
The same authors performed a subsequent metaanalysis using individual participant data from nearly 30 000 patients (including adults and children) hospitalized with pandemic H1N1 2009 influenza [6 && ]. Propensity scoring was used to adjust for confounding variables. In this analysis, a significant reduction in mortality was observed with NAI treatment at any time vs. no NAI treatment. The mortality benefit of NAI treatment was not seen with commencement after 48 h of symptoms duration in the main cohort but was maintained beyond 48 h of symptoms duration in patients admitted to critical care units, suggesting continued benefits even with late administration in more severely unwell patients. Among children (aged <16 years), the association between NAI use and mortality benefit did not reach statistical significance, however, NAI treatment at any time vs. none was found to significantly reduce mortality in pregnant women, a patient group identified as high risk by PHE [1, 4] .
CURRENT USE OF NEURAMINIDASE INHIBITORS IN CLINICAL PRACTICE
Internationally, there is a great variation in the use of NAIs [5, 28, 29] . Despite the potential benefits of NAI treatment, studies suggest that most community-dwelling patients with influenza who are at high risk of complications do not seek medical attention early enough during their course of illness for optimum NAI treatment. Even when patients do present early, only a minority are tested and prescribed an antiviral medication in line with guidelines recommendations [30] [31] [32] . For hospitalized patients, treatment of suspected seasonal influenza with NAIs appears to have increased following the H1N1 2009 pandemic [33, 34] but still remains suboptimal and is often delayed because of the slow turnaround time of laboratory testing [35] .
Most national guidelines recommend the empirical use of NAIs in patient with suspected influenza prior to the results of laboratory testing because of the slow turnaround time for test results and the need for prompt treatment [1] [2] [3] 5] . As the accuracy of clinician-diagnosed influenza is low [36, 37] this strategy exposes a large number of patients who do not have influenza to NAIs with the consequential risk of side-effects such as nausea and vomiting [1] [2] [3] 38] . Although they are used in many counties, antigen-based rapid diagnostic tests and digital immunoassays for influenza lack sensitivity [39] [40] [41] and have not been shown to be of clinical benefit or cost-effective in a randomized controlled trial [42] . Newer rapid molecular test platforms have equivalent diagnostic accuracy to laboratory PCR and can be used at the point-of-care to direct NAI use [43] [44] [45] . Recently, a large randomized controlled trial demonstrated that routine molecular point-of-care testing for respiratory viruses in hospitalized adults was effective in increasing the early detection of influenza and preventing unnecessary NAI exposure in influenzauninfected patients, in addition to other benefits including the rational use of isolation facilities [46 & ,47].
CONCLUSION
There is a growing body of evidence that NAI use (mostly oseltamivir) for the treatment of influenza is associated with improved clinical outcomes. In community-dwelling patients, randomized controlled trials have shown a reduction in the duration of illness but have not reliably shown a reduction in the rate of complications or hospitalization. Subsequently, observational studies from the H1N1 2009 pandemic have suggested a reduction in the rate of hospitalization in patients in the community. For hospitalized patients, there have been no placebocontrolled randomized controlled trials evaluating the impact of NAI treatment but observational studies including a very large and well-controlled metaanalysis from the H1N1 2009 pandemic suggests a reduction in mortality with NAI use in adults. Evidence in all groups consistently demonstrates that earlier administration is associated with the greatest benefit. Current utilization of NAIs for influenza, especially in the community is sub-optimal. Although some have argued for definitive randomized placebo-controlled trials of NAIs in hospitalized patients [48] , such trials are ethical difficult to justify given the widespread use of NAIs in standard care for influenza in hospitals. Strategies that improve the detection of influenza and the early use of NAIs are needed and may include the routine use of molecular point-of-care testing.
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